Top Markets
Coin of the day
AbbVie Inc. AbbVie Inc.

AbbVie Inc.

ABBV
Rang in aandelen #30
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the... AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Aandeelprijs
$208.57
Marktkapitalisatie
$368.78B
Verandering (1 dag)
0.68%
Verandering (1 jaar)
3.61%
Land
US
Handel AbbVie Inc. (ABBV)

Categorie

Operationele marge voor AbbVie Inc. (ABBV)
Operationele marge op March 2026 TTM: 26.72%
Volgens de meest recente financiële rapporten en aandelenkoers van AbbVie Inc. is de huidige operationele marge (TTM) 26.72%. Eind 2024 had het bedrijf een operationele marge van 16.22%.
Geschiedenis van de operationele marge van AbbVie Inc. van 2009 tot 2026
Operationele marge aan het einde van elk jaar
Jaar Operationele Marge Wijzigen
2026 (TTM) 26.72% -22.97%
2025 34.69% 113.87%
2024 16.22% -30.95%
2023 23.49% -24.74%
2022 31.21% -2.13%
2021 31.89% 28.54%
2020 24.81% -36.43%
2019 39.03% 100.26%
2018 19.49% -42.39%
2017 33.83% -7.14%
2016 36.43% 10.49%
2015 32.97% 92.92%
2014 17.09% -43.30%
2013 30.14% -4.77%
2012 31.65% 52.53%
2011 20.75% -31.20%
2010 30.16% -13.08%
2009 34.70% 0.00%
Operationele marge van vergelijkbare bedrijven of concurrenten
Bedrijf Operationele Marge Verschil in operationele marge Land
45.56% -98.29%
US
23.28% -99.13%
GB
27.17% -98.98%
US
31.24% -98.83%
CH
41.19% -98.46%
US
Wat is de Operationele marge van een bedrijf?
De Operationele marge is een belangrijke indicator om de winstgevendheid van een bedrijf te beoordelen. Hogere operationele marges zijn over het algemeen beter omdat ze aangeven dat een bedrijf zijn producten of diensten veel duurder kan verkopen dan de productiekosten. De Operationele marge wordt berekend door de winst van een bedrijf te delen door de omzet.